President, Focus IP Group, LLC, Massachusetts, US.
Healthc Policy. 2022 May;17(4):26-36. doi: 10.12927/hcpol.2022.26829.
This paper reviews the response by public sector research organizations and their technology transfer offices to the COVID-19 pandemic. It shows that leading universities and technology transfer associations quickly enacted licensing principles for the duration of the pandemic to maximize availability and minimize delays in translating public sector research institutes' (PSRIs') COVID-19 inventions to the public - in both the developed and the developing world - while waiving payment of royalties. It discusses examples of vaccines, drugs, diagnostics and personal protective equipment that were developed in PSRIs and swiftly deployed throughout the world on socially responsible terms. It reviews the case cited by Herder et al. (2022) and concludes that their proposed mandates are unnecessary and may inhibit the free flow of healthcare innovation from bench to bedside.
本文回顾了公共部门研究机构及其技术转让办公室对 COVID-19 大流行的反应。研究表明,在大流行期间,领先的大学和技术转让协会迅速制定了许可原则,以最大限度地提高公共部门研究机构(PSRIs)的 COVID-19 发明的可及性,并将其快速转化为公共产品,同时免除特许权使用费。本文还讨论了在 PSRIs 中开发的疫苗、药物、诊断和个人防护设备的例子,这些发明迅速以负责任的社会条件在全球范围内部署。本文还审查了 Herder 等人(2022 年)提出的案例,并得出结论,他们提出的授权是不必要的,可能会阻碍医疗创新从实验室到临床的自由流动。